Black triangle for monitored EU drugs to kick in on 1 September
This article was originally published in SRA
Executive Summary
As of 1 September, the product information for all new EU drugs that are subjected to additional monitoring under the pharmacovigilance legislation will have to bear an inverted black triangle1.